Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Endocrine Sensitive HER2+/HR+ Breast Cancer”

4 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 4 of 4 results

Early research (Phase 1)Looking for participantsNCT07029399
What this trial is testing

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

Who this might be right for
HR+ Breast CancerTriple Negative Breast Cancer (TNBC)CCNE1 Amplified Advanced Solid Tumors+1 more
NiKang Therapeutics, Inc. 361
Testing effectiveness (Phase 2)Looking for participantsNCT05579366
What this trial is testing

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Who this might be right for
High Grade Epithelial Ovarian CancerHigh Grade Serous Ovarian CancerPrimary Peritoneal Carcinoma+12 more
Genmab 884
Not applicableStudy completedNCT06307457
What this trial is testing

HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.

Who this might be right for
Breast Cancer
Pfizer 604
Testing effectiveness (Phase 2)Study completedNCT02411344
What this trial is testing

Preoperative Study With Trastuzumab, Pertuzumab and Letrozole in Breast Cancer Patients Sensitive to Hormonal Therapy

Who this might be right for
Endocrine Sensitive HER2+/HR+ Breast Cancer
Istituto Oncologico Veneto IRCCS 64